Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

61 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting cancer with kinase inhibitors.
Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Gross S, et al. Among authors: hoeflich kp. J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1. J Clin Invest. 2015. PMID: 25932675 Free PMC article. Review.
p21-activated kinase inhibitors.
Rudolph J, Crawford JJ, Hoeflich KP, Chernoff J. Rudolph J, et al. Among authors: hoeflich kp. Enzymes. 2013;34 Pt. B:157-80. doi: 10.1016/B978-0-12-420146-0.00007-X. Epub 2013 Nov 7. Enzymes. 2013. PMID: 25034104 Review.
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells.
Ong CC, Jubb AM, Haverty PM, Zhou W, Tran V, Truong T, Turley H, O'Brien T, Vucic D, Harris AL, Belvin M, Friedman LS, Blackwood EM, Koeppen H, Hoeflich KP. Ong CC, et al. Among authors: hoeflich kp. Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7177-82. doi: 10.1073/pnas.1103350108. Epub 2011 Apr 11. Proc Natl Acad Sci U S A. 2011. PMID: 21482786 Free PMC article.
p21-Activated kinase inhibitors: a patent review.
Crawford JJ, Hoeflich KP, Rudolph J. Crawford JJ, et al. Among authors: hoeflich kp. Expert Opin Ther Pat. 2012 Mar;22(3):293-310. doi: 10.1517/13543776.2012.668758. Epub 2012 Mar 11. Expert Opin Ther Pat. 2012. PMID: 22404134 Review.
ERK inhibition overcomes acquired resistance to MEK inhibitors.
Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K, Ha C, Zhou W, Song K, Friedman LS, Amler LC, Hampton GM, Moffat J, Belvin M, Lackner MR. Hatzivassiliou G, et al. Among authors: hoeflich kp. Mol Cancer Ther. 2012 May;11(5):1143-54. doi: 10.1158/1535-7163.MCT-11-1010. Epub 2012 Mar 8. Mol Cancer Ther. 2012. PMID: 22402123
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.
Ong CC, Jubb AM, Jakubiak D, Zhou W, Rudolph J, Haverty PM, Kowanetz M, Yan Y, Tremayne J, Lisle R, Harris AL, Friedman LS, Belvin M, Middleton MR, Blackwood EM, Koeppen H, Hoeflich KP. Ong CC, et al. Among authors: hoeflich kp. J Natl Cancer Inst. 2013 May 1;105(9):606-7. doi: 10.1093/jnci/djt054. Epub 2013 Mar 27. J Natl Cancer Inst. 2013. PMID: 23535073
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Junttila MR, Devasthali V, Cheng JH, Castillo J, Metcalfe C, Clermont AC, Otter DD, Chan E, Bou-Reslan H, Cao T, Forrest W, Nannini MA, French D, Carano R, Merchant M, Hoeflich KP, Singh M. Junttila MR, et al. Among authors: hoeflich kp. Mol Cancer Ther. 2015 Jan;14(1):40-7. doi: 10.1158/1535-7163.MCT-14-0030. Epub 2014 Nov 5. Mol Cancer Ther. 2015. PMID: 25376606
Inhibitors of p21-activated kinases (PAKs).
Rudolph J, Crawford JJ, Hoeflich KP, Wang W. Rudolph J, et al. Among authors: hoeflich kp. J Med Chem. 2015 Jan 8;58(1):111-29. doi: 10.1021/jm501613q. Epub 2014 Dec 3. J Med Chem. 2015. PMID: 25415869
61 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page